Implement feature SONE-217: add a searchable, paginated "Change History" panel to the Item Detail view that shows who changed an item, when, the fields changed, and before/after values, with filtering by user, date range, and field.
| Property | Value / Observation | |----------|---------------------| | Core scaffold | Pyrrolidine‑carboxamide linked to a 4‑(trifluoromethyl)phenyl ring and a 1‑oxo‑pyridine side chain. | | Selectivity | > 500‑fold selectivity for NLRP3 over NLRP1, NLRC4, AIM2 (biochemical ATPase assay). | | In‑vitro potency | IC₅₀ ≈ 12 nM in THP‑1 macrophage IL‑1β release assay (LPS + nigericin trigger). | | Pharmacokinetics (rat) | Oral F% ≈ 58 %; t½ ≈ 9 h; Cmax at 2 h; low hepatic extraction ratio (Eₕ ≈ 0.15). | | Metabolism | Primarily CYP3A4 oxidation; minor glucuronidation (UGT1A9). No reactive metabolites identified in 28‑day rat toxicology. | | Safety window (pre‑clinical) | NOAEL = 150 mg kg⁻¹ day⁻¹ (rat 28‑day study); margin > 30‑fold vs. projected human therapeutic exposure (≈ 2 mg kg⁻¹ bid). | | Formulation | Immediate‑release tablet (30 mg, 60 mg) with HPMC‑based matrix; food‑effect study shows < 20 % AUC change. | SONE-217
Key takeaway: The drug‑likeness of SONE‑217 supports a once‑ or twice‑daily oral dosing regimen, a major advantage over injectable IL‑1 blockers. | Agent | Modality | Target | Route
| Agent | Modality | Target | Route | Development Stage | |-------|----------|--------|-------|-------------------| | Canakinumab (Ilaris) | mAb | IL‑1β | SC q8 wks | Approved (various CV & inflammatory indications) | | Anakinra (Kineret) | Recombinant protein | IL‑1R | SC daily | Approved (RA, CAPS) | | Dapansutrile (OLT1177) | Small molecule | NLRP3 (covalent) | Oral | Phase 2 (Gout, HF) | | MCC950 (pre‑clinical) | Small molecule | NLRP3 (non‑covalent) | Oral | Academic only | | SONE‑217 | Small molecule | NLRP3 (ATPase pocket) | Oral | Phase 1/2 (2024‑2026) | SONE‑217 (chemical name: (2S
Differentiators for SONE‑217
SONE‑217 (chemical name: (2S,4R)-4‑[4‑(trifluoromethyl)phenyl]‑2‑[(1‑oxo‑1,2‑dihydro‑pyridin‑3‑yl)‑methyl]‑pyrrolidine‑1‑carboxamide) is an orally bioavailable, highly selective small‑molecule modulator currently being developed by Sone Therapeutics Ltd. (formerly a spin‑out of the University of Cambridge’s Department of Chemical Biology).
Bottom line: SONE‑217 is positioned as a “first‑in‑class” oral NLRP3 inhibitor that could replace injectable biologics for a range of chronic inflammatory diseases.